RWD

COTA Announces Strategic Collaboration with Sanofi to Leverage Real-World Data and AI to Accelerate Cancer Trials

Retrieved on: 
Mercredi, avril 17, 2024
Health Technology, Health, Oncology, Disease, Cancer, Multiple myeloma, Partnership, Patient, Sanofi, Trial of the century, RWD, Artificial intelligence, Pharmacy, Medical imaging

COTA , a leader in real-world data (RWD) and analytics for oncology, today announced a strategic collaboration with Sanofi to use RWD and artificial intelligence (AI) to increase the speed of oncology trials, including for multiple myeloma.

Key Points: 
  • COTA , a leader in real-world data (RWD) and analytics for oncology, today announced a strategic collaboration with Sanofi to use RWD and artificial intelligence (AI) to increase the speed of oncology trials, including for multiple myeloma.
  • The partnership will be valuable to understand clinical outcomes that may ultimately be beneficial for patients living with cancer.
  • COTA’s RWD offers critical insights into effective cancer treatment pathways and will provide valuable context on key patient populations.
  • “Our collaboration with Sanofi has the potential to enable more patients and their families to benefit from breakthrough treatments in an expedited time frame,” said Dr. C.K.

NCCN and Flatiron Health Announce Collaboration to Improve Cancer Care Quality with Real-World Data

Retrieved on: 
Mercredi, avril 10, 2024
Technology, Health, Other Philanthropy, Artificial Intelligence, Philanthropy, Oncology, Research, Software, Managed Care, General Health, Health Technology, Foundation, Science, Data Management, Education, Cancer, NCCN, Flatiron, Learning, National Comprehensive Cancer Network, MD, RWD

Flatiron Health , a leading healthtech company dedicated to improving cancer care and advancing research using real-world data (RWD), today announced the renewal of their collaboration with the National Comprehensive Cancer Network ® (NCCN®), an alliance of leading cancer centers devoted to patient care, research, and education.

Key Points: 
  • Flatiron Health , a leading healthtech company dedicated to improving cancer care and advancing research using real-world data (RWD), today announced the renewal of their collaboration with the National Comprehensive Cancer Network ® (NCCN®), an alliance of leading cancer centers devoted to patient care, research, and education.
  • The collaboration between Flatiron and the NCCN dates back to 2014, when Flatiron Health first launched a cloud-based repository of NCCN Member Institution data—the NCCN Quality & Outcomes Database.
  • Additionally, Flatiron and NCCN will continue to work together to support quality improvement initiatives at participating NCCN Member Institutions through the continued development of metrics and benchmarks to assess, measure, and impact quality of care.
  • “This collaboration will expand the impact of real-world data in addressing evidence gaps and improving care standards along with leading cancer centers in the NCCN alliance.”

Introducing Citeline PatientMatch for Precision Patient Recruitment

Retrieved on: 
Jeudi, avril 25, 2024
Doctor of Philosophy, EMR, ChromeOS, Patient, RWD, Diagnosis, Biomarker, Clinical trial, Algorithm, MD, Medical imaging

NEW YORK, April 25, 2024 /PRNewswire-PRWeb/ -- Due to more complex protocol designs, stricter inclusion/exclusion criteria and shorter intervals between diagnosis and treatment, the window for identifying the right patients to enroll in clinical trials is shrinking. With Citeline PatientMatch, sponsors and investigators receive customized support to pinpoint eligible patients before a treatment plan is finalized.

Key Points: 
  • Introducing Citeline PatientMatch, delivering custom-timed alerts when patients receive lab or biomarker results that could make them eligible for a clinical trial.
  • Citeline PatientMatch is a fit-for-purpose recruitment approach that strongly aligns to many therapeutic indications where traditional, direct-to-patient recruitment advertising approaches have historically been unsuccessful," says Matt Holms, Vice President, Sales-Patient Engagement & Recruitment at Citeline.
  • Citeline PatientMatch is part of the Citeline Connect end-to-end suite of patient engagement and recruitment solutions.
  • With the addition of Citeline PatientMatch, Citeline Connect expands and strengthens its capacity for meeting enrollment goals and enhancing clinical trial diversity.

NashBio and CuriMeta Collaborate to Expand and Diversify Advanced Real-World Health Datasets

Retrieved on: 
Jeudi, avril 25, 2024
Genomics, AUC, Vanderbilt University, EMR, Research, Pathology, Disease, Radiology, DNA, Therapy, Science, RWD, Medicine, Vanderbilt University Medical Center, Organization, Pharmaceutical industry

ST. LOUIS, April 25, 2024 /PRNewswire/ -- CuriMeta, a leading expert in life science-focused, advanced real-world health data, and NashBio, a leading real-world, multi-omics data company, today announced a data licensing agreement that will bring together each organizations' distinct expertise in real-world data (RWD).

Key Points: 
  • NashBio provides real-world clinical, genomic and imaging data to their healthcare and life science research partners through their biobank, BioVU®.
  • This advanced RWD helps advance novel discoveries and the development of new, more personalized therapeutics and diagnostics.
  • "At NashBio, we say smarter data is in our DNA", said Leeland Ekstrom, founder and CEO, NashBio.
  • "Strategic collaborations with organizations like CuriMeta enhance our datasets and biobank, bringing broader, more diverse datasets to our clients.

HealthVerity Precision Event Alerts redefine new pathways to real-time physician outreach

Retrieved on: 
Mercredi, avril 17, 2024
Labcorp, Diagnosis, Science, Quest, Patient, RWD, Physician, Pharmaceutical industry

PHILADELPHIA, April 17, 2024 /PRNewswire/ -- HealthVerity, the leader in synchronizing transformational technologies and real-world data (RWD) to advance the science, today announced the launch and commercial availability of HealthVerity Precision Event Alerts, the industry's most comprehensive, accurate and timely physician alerting solution.

Key Points: 
  • PHILADELPHIA, April 17, 2024 /PRNewswire/ -- HealthVerity, the leader in synchronizing transformational technologies and real-world data (RWD) to advance the science, today announced the launch and commercial availability of HealthVerity Precision Event Alerts , the industry's most comprehensive, accurate and timely physician alerting solution.
  • While standard trigger programs can help commercial pharmaceutical teams discover physicians of interest, these legacy approaches are challenged with long lag times and numerous false alerts.
  • By leveraging an expansive yet proprietary combination of lab data, open clearinghouse medical claims and closed medical payer claims, HealthVerity Precision Event Alerts delivers 15% to 40% more alerts with 20% greater accuracy in half the time.
  • "HealthVerity Precision Event Alerts make it easy to activate the optimal mix of real-world data and engage more quickly with the right providers, delivering the highest volume of alerts with the greatest accuracy."

Verana Health Developing Qdata® Dry Eye Disease, the Largest Real-World Dataset of its Kind

Retrieved on: 
Jeudi, avril 4, 2024
Prevalence, Dry eye syndrome, ASCRS, SAN, Patient, Ophthalmology, Research, RWD, American Academy, Cataract, DED, Society, Data, Telecanthus, Health, Annual general meeting, Nursing

Qdata DED represents a significant advancement in ophthalmology research, and is the largest of its kind, featuring an extensive dataset that will include outcomes and clinical information on more than 10 million de-identified patients with DED and related ocular conditions.

Key Points: 
  • Qdata DED represents a significant advancement in ophthalmology research, and is the largest of its kind, featuring an extensive dataset that will include outcomes and clinical information on more than 10 million de-identified patients with DED and related ocular conditions.
  • “We’re harnessing the power of real-world evidence to transform patient care and expedite the development of crucial therapies,” said Sujay Jadhav, CEO of Verana Health.
  • Dry eye disease affects nearly 16 million Americans , posing significant challenges for patients and ophthalmologists alike.
  • Verana Health remains at the forefront of this transformation, continuously expanding its Qdata offerings to meet the growing needs of life sciences teams and clinicians.

MMS Hires Pharmaceutical Industry Veteran James Zee for Global Biometrics Leadership in Europe Amid Strong Regional Growth

Retrieved on: 
Jeudi, avril 4, 2024
Data Management, Technology, Pharmaceutical, Professional Services, Biometrics, Medical Devices, Genetics, Artificial Intelligence, Clinical Trials, Science, Biotechnology, Software, Data Analytics, Health, Research, MSD, American City Business Journals, Growth, AstraZeneca, Data science, Novartis, Patient, Roche, MMS, RWD, AI, Statistics, Data management, Drug development, NCE, FSP, Zee, Fine chemical

MMS, a leading, data-focused clinical research organization (CRO), announced today that the company has expanded its biometrics leadership within European operations by hiring James Zee as Director of Global Statistical Programming.

Key Points: 
  • MMS, a leading, data-focused clinical research organization (CRO), announced today that the company has expanded its biometrics leadership within European operations by hiring James Zee as Director of Global Statistical Programming.
  • Based in the United Kingdom (UK), Zee brings 25 years of experience across several leading pharmaceutical companies, including AstraZeneca, MSD, Novartis, Roche, and others.
  • With extended drug development experience, Zee helps to guide the statistical programming team at MMS to support some of the timely execution and evolving regulations for the development of NCEs.
  • Since 2020, the global biometrics CRO has experienced 133 percent growth in Europe.

Komodo Health Introduces New No-Code Analytics Application To Visualize Real-World Healthcare Data in Minutes

Retrieved on: 
Mardi, mars 19, 2024
Software, General Health, Professional Services, Data Management, Apps, Applications, Technology, Artificial Intelligence, Health Technology, Data Analytics, Science, Other Science, Health, Diagnosis, Consultant, Benchmarking, Growth, Entrepreneurship, Data science, Multiple sclerosis, Intelligence, Patient, Synovial joint, RWD, Commercial, Senior, Drug, Workflow, Fine chemical

MapView is the industry’s first and most sophisticated analytics application that allows users without data science expertise to easily extract insights from Komodo’s Healthcare Map.

Key Points: 
  • MapView is the industry’s first and most sophisticated analytics application that allows users without data science expertise to easily extract insights from Komodo’s Healthcare Map.
  • MapView, an application within the company’s MapLab platform, accelerates and automates insight generation for some of the most common analyses performed in healthcare.
  • MapView introduces Komodo’s first wave of pre-built templates that are tailored to a range of essential industry use cases.
  • Additional MapLab applications and segment-specific offerings, including Komodo’s new generative AI analytics co-pilot, will launch throughout 2024.

Alpha Motor Corporation Advances Preproduction of WOLF Electric Truck, Introduces Base Model Details

Retrieved on: 
Lundi, mars 25, 2024
WOLF, EV, The Wolf, Alpha Motor Corporation, BLI, Growth, Bottom line, EVS, RWD, Transport, Interview, Patent, Car

IRVINE, Calif., March 25, 2024 /PRNewswire/ -- Alpha Motor Corporation (Alpha) is pleased to announce the WOLF electric truck base model (single motor RWD) , marking a step towards mainstream accessibility to electric vehicles.

Key Points: 
  • IRVINE, Calif., March 25, 2024 /PRNewswire/ -- Alpha Motor Corporation (Alpha) is pleased to announce the WOLF electric truck base model (single motor RWD) , marking a step towards mainstream accessibility to electric vehicles.
  • Following the successful validation of the WOLF's driving performance, Alpha is ramping up the manufacturing of test vehicles and advancing pre-production.
  • Alpha Motor is building an electric vehicle business the right way.
    "
  • Alpha Motor is building an electric vehicle business the right way .

Pioneering the Next Frontier: ArisGlobal Unveils Cutting-Edge Safety & Regulatory Product Offerings Powered by Generative AI

Retrieved on: 
Mercredi, mars 20, 2024
Automation, Synthetic media, Digital, Partnership, Health, RWD, Health information management, Nature, Deep learning, Ecosystem, Generative, Mobile phone

LONDON, March 20, 2024 /PRNewswire/ -- ArisGlobal, an innovative life sciences technology company and creator of LifeSphere®, today announced three cutting-edge product offerings that will transform pharmacovigilance and regulatory operations. At Breakthrough2024, its annual industry event, the company unveiled Advanced Intake powered by LifeSphere NavaX; an unprecedented Real-World Data subscription in partnership with OMNY Health; and its groundbreaking next-generation LifeSphere Regulatory platform.

Key Points: 
  • ArisGlobal introduced Advanced Intake, powered by LifeSphere NavaX and leveraging Generative AI to revolutionize adverse event intake and overcome recognized pain points.
  • With this offering, ArisGlobal has become the first life sciences R&D technology company to announce innovative offerings with Generative AI.
  • ArisGlobal also launched the latest innovations for its LifeSphere Regulatory platform - the most intelligent, connected, and comprehensive platform available to the regulatory community.
  • The next-generation LifeSphere Regulatory platform offers intelligent automation across powerful AI and deep learning use cases for regulatory processes, harnessing Generative AI.